• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $IOVA

    Iovance Biotherapeutics Inc.

    Subscribe to $IOVA
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

    IPO Year:

    Exchange: NASDAQ

    Website: iovance.com

    Peers

    $ATRA

    Recent Analyst Ratings for Iovance Biotherapeutics Inc.

    DatePrice TargetRatingAnalyst
    5/9/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    10/24/2024$17.00Buy
    UBS
    7/29/2024$19.00 → $10.00Overweight → Neutral
    Piper Sandler
    11/20/2023$12.00Buy
    Goldman
    9/18/2023$40.00 → $18.00Overweight
    Barclays
    5/30/2023$11.00 → $17.00Equal Weight → Overweight
    Wells Fargo
    3/27/2023$11.00Equal Weight
    Wells Fargo
    1/27/2023$11.00 → $14.00Neutral → Overweight
    Piper Sandler
    12/9/2022$20.00 → $6.00Buy → Neutral
    Goldman
    10/31/2022Neutral
    Guggenheim
    See more ratings

    Iovance Biotherapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

      SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday, May 8, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on May 8, 2025 at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wi5b4tnt. The live and archived webcast can be accessed in the Investors sectio

      5/2/25 4:01:39 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Announces Participation in Upcoming Scientific Congresses

      SAN CARLOS, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, announced that pre-clinical data for IOV-5001, a genetically engineered, inducible, and tethered interleukin-12 (IL-12) TIL cell therapy, will be presented at the 2025 AACR Annual Meeting. In addition, five-year outcomes data from the C-144-01 study of lifileucel monotherapy in patients with advanced melanoma, and a poster on study design for lifileucel in frontline advanced non-small cell lung cancer, will be presented at the 2025

      4/23/25 4:15:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      SAN CARLOS, Calif., April 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on April 17, 2025 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 297,600 shares of Iovance's common stock to fifty new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, March 13

      4/18/25 5:30:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Traws Pharma Announces Management Updates

      Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

      3/28/25 4:30:00 PM ET
      $IKNA
      $IOVA
      $TRAW
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      SAN CARLOS, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on March 20, 2025 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 308,710 shares of Iovance's common stock to forty-three new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, Ma

      3/21/25 5:15:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      SAN CARLOS, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on February 21, 2025 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 328,730 shares of Iovance's common stock to seventy-one new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022

      2/21/25 5:15:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025

      SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full year 2024 financial results and corporate updates on Thursday, February 27, 2025. Fourth Quarter and Full Year 2024 Audio WebcastManagement will host a live audio webcast to discuss these results and provide a corporate update on February 27, 2025 at 4:30 p.m. EST. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/hw2g9axf/. Upcoming

      2/18/25 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on February 10, 2025 (the "Date of Grant"), the Company approved the grant of inducement stock options and restricted stock units covering an aggregate of up to 305,000 shares of Iovance's common stock to Daniel Kirby, the Company's new Chief Commercial Officer. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on Septembe

      2/12/25 5:30:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

      SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership team in the newly created role of Chief Commercial Officer, effective today. "I would like to extend a warm welcome to Dan Kirby on behalf of the entire Iovance team," stated Frederick Vogt, Ph.D., J.D., Interim President, Chief Executive Officer and board member of Iovance. "Dan has been instrumental in building and leading cell therapy comm

      2/10/25 7:00:00 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

      SAN CARLOS, Calif., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on January 16, 2025 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 224,550 shares of Iovance's common stock to forty-one new, non-executive employees. The awards were granted under Iovance's Amended and Restated 2021 Inducement Plan, which was adopted on September 22, 2021 and amended and restated on January 12, 2022, Mar

      1/17/25 5:00:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Iovance Biotherapeutics Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Iovance Biotherapeutics Inc.

      10-Q - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      5/8/25 5:15:56 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      5/8/25 4:05:33 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Iovance Biotherapeutics Inc.

      DEFA14A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      4/28/25 5:05:47 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Iovance Biotherapeutics Inc.

      DEF 14A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      4/28/25 5:00:56 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-K filed by Iovance Biotherapeutics Inc.

      10-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      2/27/25 5:15:54 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      2/27/25 4:05:20 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Iovance Biotherapeutics Inc.

      SCHEDULE 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      2/14/25 4:15:03 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      2/10/25 7:22:01 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Iovance Biotherapeutics Inc.

      S-8 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      12/13/24 5:16:13 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

      8-K - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Filer)

      11/21/24 5:15:17 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Iovance Biotherapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mcpeak Merrill A bought $2,287,500 worth of shares (250,000 units at $9.15), increasing direct ownership by 356% to 320,150 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      2/20/24 7:52:18 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dukes Iain D. bought $292,800 worth of shares (32,000 units at $9.15), increasing direct ownership by 145% to 54,000 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      2/20/24 4:21:48 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rothbaum Wayne P. bought $45,750,000 worth of shares (5,000,000 units at $9.15) (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      2/20/24 4:11:20 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Mcpeak Merrill A bought $55,600 worth of shares (10,000 units at $5.56)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      9/19/23 4:30:34 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Iovance Biotherapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Regulatory Officer Puri Raj K. converted options into 8,334 shares and covered exercise/tax liability with 2,509 shares, increasing direct ownership by 3% to 201,252 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      3/18/25 8:30:18 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Interim CEO & General Counsel Vogt Frederick G

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      3/7/25 8:06:49 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Regulatory Officer Puri Raj K.

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      3/7/25 8:06:26 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Graf Finckenstein Friedrich

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      3/7/25 8:06:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Bilinsky Igor

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      3/7/25 8:05:40 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Bellemin Jean-Marc

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      3/7/25 8:05:11 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Financial Officer Bellemin Jean-Marc converted options into 58,590 shares and covered exercise/tax liability with 31,734 shares, increasing direct ownership by 92% to 56,204 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      3/5/25 8:33:41 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Operating Officer Bilinsky Igor covered exercise/tax liability with 33,302 shares and converted options into 62,106 shares, increasing direct ownership by 49% to 87,578 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      3/5/25 8:32:49 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Interim CEO & General Counsel Vogt Frederick G converted options into 223,943 shares and covered exercise/tax liability with 95,413 shares, increasing direct ownership by 58% to 349,646 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      3/5/25 8:32:01 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Regulatory Officer Puri Raj K. converted options into 59,999 shares and covered exercise/tax liability with 19,984 shares, increasing direct ownership by 26% to 195,427 units (SEC Form 4)

      4 - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Issuer)

      3/5/25 8:31:07 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Iovance Biotherapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      11/14/24 4:50:30 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc.

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      10/18/24 8:38:16 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Iovance Biotherapeutics Inc. (Amendment)

      SC 13D/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      3/19/24 5:19:45 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Iovance Biotherapeutics Inc.

      SC 13G - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      3/1/24 7:09:58 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc. (Amendment)

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      2/14/24 4:29:08 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc. (Amendment)

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      2/14/24 6:16:06 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc. (Amendment)

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      2/13/24 5:07:58 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc. (Amendment)

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      2/9/24 5:40:28 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc. (Amendment)

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      1/26/24 11:49:45 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Iovance Biotherapeutics Inc. (Amendment)

      SC 13G/A - IOVANCE BIOTHERAPEUTICS, INC. (0001425205) (Subject)

      1/25/24 10:49:53 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Iovance Biotherapeutics Inc. FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

      For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

      2/16/24 3:48:47 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Iovance Biotherapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Iovance Biotherapeutics downgraded by Citizens JMP

      Citizens JMP downgraded Iovance Biotherapeutics from Mkt Outperform to Mkt Perform

      5/9/25 8:42:44 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • UBS initiated coverage on Iovance Biotherapeutics with a new price target

      UBS initiated coverage of Iovance Biotherapeutics with a rating of Buy and set a new price target of $17.00

      10/24/24 6:22:38 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Iovance Biotherapeutics from Overweight to Neutral and set a new price target of $10.00 from $19.00 previously

      7/29/24 7:40:13 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman initiated coverage on Iovance Biotherapeutics with a new price target

      Goldman initiated coverage of Iovance Biotherapeutics with a rating of Buy and set a new price target of $12.00

      11/20/23 7:45:27 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Barclays reiterated coverage on Iovance Biotherapeutics with a new price target

      Barclays reiterated coverage of Iovance Biotherapeutics with a rating of Overweight and set a new price target of $18.00 from $40.00 previously

      9/18/23 1:32:31 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Iovance Biotherapeutics from Equal Weight to Overweight and set a new price target of $17.00 from $11.00 previously

      5/30/23 10:22:21 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wells Fargo resumed coverage on Iovance Biotherapeutics with a new price target

      Wells Fargo resumed coverage of Iovance Biotherapeutics with a rating of Equal Weight and set a new price target of $11.00

      3/27/23 8:59:03 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Iovance Biotherapeutics from Neutral to Overweight and set a new price target of $14.00 from $11.00 previously

      1/27/23 7:17:23 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics downgraded by Goldman with a new price target

      Goldman downgraded Iovance Biotherapeutics from Buy to Neutral and set a new price target of $6.00 from $20.00 previously

      12/9/22 7:36:14 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Guggenheim initiated coverage on Iovance Biotherapeutics

      Guggenheim initiated coverage of Iovance Biotherapeutics with a rating of Neutral

      10/31/22 7:42:28 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    Iovance Biotherapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more

    Iovance Biotherapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Traws Pharma Announces Management Updates

      Werner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the retirement of Werner Cautreels, PhD, Chief Executive Officer (CEO), effective on or about close of business on March 31, 2025 after the Company files its Annual Report on Form 10-K with the Securities and Exchange Commission. Iain D. Dukes, D Phil, will assum

      3/28/25 4:30:00 PM ET
      $IKNA
      $IOVA
      $TRAW
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

      SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that Dan Kirby will join the Company's executive leadership team in the newly created role of Chief Commercial Officer, effective today. "I would like to extend a warm welcome to Dan Kirby on behalf of the entire Iovance team," stated Frederick Vogt, Ph.D., J.D., Interim President, Chief Executive Officer and board member of Iovance. "Dan has been instrumental in building and leading cell therapy comm

      2/10/25 7:00:00 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cara Therapeutics Appoints Ryan Maynard as Chief Financial Officer

      STAMFORD, Conn., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the appointment of Ryan Maynard as Chief Financial Officer (CFO), effective immediately. As a member of the Executive Leadership Team, Mr. Maynard will lead the Company's financial operations. "Ryan's deep financial leadership experience will be instrumental to the execution of Cara's long-term growth strategy as we continue to maximize the KORSUVA™ (difelikefalin) injection launch and advance our oral difelikefalin pipeline to establish our position

      9/12/22 7:00:00 AM ET
      $CARA
      $IOVA
      $RIGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Iovance Biotherapeutics Appoints Wendy L. Dixon, Ph.D., to Board of Directors

      SAN CARLOS, Calif., June 13, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today announced the appointment of Wendy L. Dixon, Ph.D., to the company's Board of Directors, effective June 10, 2022. Dr. Dixon has more than 40 years of experience in the biopharmaceutical industry, building and leading organizations and launching and growing more than 20 major global pharmaceutical products, including many highly successful multibillion dollar global brands. Iain Dukes, D. Phil., Chairman of the Board of Direc

      6/13/22 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BIOMEA Fusion Strengthens its Executive Team with Appointment of Franco Valle as Chief Financial Officer

      REDWOOD CITY, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a preclinical-stage biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, announced the appointment of Franco Valle as Chief Financial Officer. Mr. Valle is an accomplished financial expert who brings extensive experiences to Biomea, in particular with building the necessary infrastructure to support clinical and operational growth within biotech companies. Mr. Valle will also assume the role of Principal Financial Officer and Principal Accounting Officer upon joining. Recently, Mr. Valle se

      6/28/21 7:10:00 PM ET
      $IOVA
      $BBIO
      $EIDX
      $BMEA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Major Pharmaceuticals
    • Iovance Biotherapeutics Appoints Igor Bilinsky as Chief Operating Officer

      SAN CARLOS, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appointment of Igor Bilinsky, Ph.D., as Chief Operating Officer, effective today. Dr. Bilinsky brings more than 20 years of biotechnology industry experience as a senior executive and consultant, including public companies. “I am pleased to welcome Igor to Iovance and look forward to his contributions while we advance our TIL cell therapy pipeline,” stated Maria Fardis, Ph.D., President and Chief Executive Officer of Iovance Biotherapeutics. “Through his experience in several senior

      3/15/21 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics to Host First Quarter 2025 Financial Results and Corporate Updates Webcast on Thursday, May 8, 2025

      SAN CARLOS, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2025 financial results and corporate updates on Thursday, May 8, 2025. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update on May 8, 2025 at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wi5b4tnt. The live and archived webcast can be accessed in the Investors sectio

      5/2/25 4:01:39 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates on February 27, 2025

      SAN CARLOS, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full year 2024 financial results and corporate updates on Thursday, February 27, 2025. Fourth Quarter and Full Year 2024 Audio WebcastManagement will host a live audio webcast to discuss these results and provide a corporate update on February 27, 2025 at 4:30 p.m. EST. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/hw2g9axf/. Upcoming

      2/18/25 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024

      Significant Demand for Amtagvi™ (Lifileucel) Continues with $58.6M in Total 3Q24 Product Revenue Reaffirming Guidance of $160-$165M for FY24 and $450-$475M for FY25 of Total Product Revenue Marketing Authorization Applications Validated and Accepted for Review by European Regulatory Authorities for Potential Approval Starting with the UK in 1H2025 and EU and Canada in 2H2025 Enrollment Accelerating in IOV-LUN-202 Registrational Phase 2 Trial in Post-anti-PD-1 NSCLC SAN CARLOS, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lym

      11/7/24 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024

      SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter and year to date 2024 financial results on Thursday, November 7, 2024. Q3 2024 Financial Results Conference CallManagement will host a conference call and live audio webcast to discuss these results and provide a corporate update on November 7, 2024 at 4:30 p.m. EST. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/vxykqwaf. The live and arch

      10/31/24 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2024

      Strong Momentum Continues for Amtagvi™ (Lifileucel) U.S. Launch with $31.1 Million in Total 2Q24 Revenue Total Product Revenue Guidance of $53-$55 Million for 3Q24, $160-$165 Million for FY24, and $450-$475 Million for FY25 SAN CARLOS, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported second quarter and first half 2024 financial results and corporate updates.  Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive Officer of Iovance, stated, "The first

      8/8/24 4:01:32 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics to Host Second Quarter and First Half 2024 Financial Results Conference Call and Webcast on Thursday, August 8, 2024

      SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/uhudv42k/. The live and archived webcast can be accessed in the Investors section of the Company's

      7/29/24 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate Updates

      Strong Momentum for Amtagvi™ (Lifileucel) U.S. Launch Following U.S. Food and Drug Administration (FDA) Approval 100+ Amtagvi Patients Enrolled Across More Than 40 Current Authorized Treatment Centers (ATCs), with ~50 Total ATCs On Track by End of May and 70+ Total ATCs by Year-End 2024 Amtagvi Regulatory Submissions on Track in the European Union (EU), United Kingdom (UK), and Canada in 2024 SAN CARLOS, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarte

      5/9/24 4:01:00 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024

      SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/m4tigan7. The live and archived webcast can be accessed in the Investors section of the Company's website, I

      5/1/24 6:01:00 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024

      SAN CARLOS, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its fourth quarter and full-year 2023 financial results on Wednesday, February 28, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To participate in the live conference call Q&A, please register at https://register.vevent.com/register/BI289df7d30f474a72a72e1c4f7a754c92. To listen to the live or archived audio webcast, please r

      2/22/24 8:45:21 AM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Iovance Biotherapeutics to Host Conference Call and Webcast on Friday, February 16, 2024

      SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will host a conference call and live audio webcast to discuss the FDA approval announced earlier today at 4:15 p.m. ET, February 16, 2024. To participate in the conference call Q&A and live audio webcast, please register at https://register.vevent.com/register/BI0633b8a73e8b4c578bfed2a8ef37003e. To listen to the live or archived webcast, please register at https://edge.media-server.com/mmc/p/uqbbcfz4/. The live and archived webcast

      2/16/24 3:38:31 PM ET
      $IOVA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care